

0734 SUPPLEMENTARY DATA

Supplementary Table S1 Characteristics of persons on drug-susceptible TB treatment regimens in all enrolled participants and in those in whom QoL was assessed*

		Enrolled (<i>n</i> = 604) <i>n</i> (%)	QoL data (<i>n</i> = 446) <i>n</i> (%)
Area	Metro Manila	305 (50.5)	270 (60.5)
	Negros Occidental	299 (49.5)	176 (39.5)
Urban sites (Metro Manila)	San Nicholas	107 (17.7)	87 (19.5)
	Pedro Gil	102 (16.9)	87 (19.5)
	San Lazaro Hospital	96 (15.9)	96 (21.5)
Rural sites (Negros Occidental)	Valladolid	77 (12.7)	22 (4.9)
	Bago City	222 (36.8)	154 (34.5)
Sex	Female	178 (29.5)	129 (28.9)
	Male	426 (70.5)	317 (71.1)
Age category, years	18–40	252 (41.7)	197 (44.2)
	41–65	270 (44.7)	192 (43.0)
	>65	82 (13.6)	57 (12.8)
Marital status	Single	239 (39.6)	188 (42.2)
	Married	284 (47.0)	203 (45.5)
	Divorced/separated	14 (2.3)	10 (2.2)
	Widowed	67 (11.1)	45 (10.1)
Maximum education obtained	Primary	215 (35.6)	145 (32.5)
	Secondary	227 (37.6)	168 (37.7)
	Tertiary	142 (23.5)	121 (27.1)
	Vocational	20 (3.3)	12 (2.7)

Household food insecurity	Food secure	307 (50.8)	234 (52.5)
	Moderate insecurity	157 (26.0)	105 (23.5)
	Severe insecurity	140 (23.2)	107 (24.0)
Smoking status	No or ex-smoker	480 (79.5)	369 (82.7)
	Yes	124 (20.5)	77 (17.3)
Alcohol consumption pre-TB	Daily	111 (18.4)	77 (17.3)
	Weekly or monthly	132 (21.9)	99 (22.2)
	Rarely/never	361 (59.8)	270 (60.5)
Phase of treatment	Intensive	309 (51.2)	240 (53.8)
	Continuation	295 (48.8)	206 (46.2)
Undernutrition [†]	Normal/mild	480 (79.5)	357 (80.0)
	Moderate/severe	121 (20.0)	88 (19.7)
Anaemia [‡]	None/mild	514 (85.1)	373 (83.6)
	Moderate/severe	85 (14.1)	70 (15.7)
Diabetes [§]	Not diabetic	507 (83.9)	409 (91.7)
	New diagnosis	27 (4.5)	19 (4.3)
	Existing diagnosis	22 (3.6)	18 (4.0)

* Missing values: anaemia ($n = 3$), undernutrition ($n = 1$).

[†] Moderate/severe: BMI ≥ 17 kg/m², mild/normal: BMI < 17 kg/m².

[‡] Moderate/severe: haemoglobin < 11 g/dL, mild/normal: haemoglobin ≥ 11 g/dL

[§] New diagnosis: previously undiagnosed with HbA1c $\geq 6.5\%$; existing: previously diagnosed with diabetes.

QoL = quality of life; TB = tuberculosis; BMI = body mass index; HbA1c = glycosylated haemoglobin.

Supplementary Table S2 Domain scores in 446 persons on drug-susceptible TB treatment regimens by demographic and socio-economic characteristics

		<i>n</i>	Health-related Quality of Life domain, mean (SD)				Global <i>P</i> value
			Physical	Psychological	Social	Environmental	
Area	Metro Manila	270	13.9 (2.4)	14.3 (2.0)	14.8 (2.0)	13.6 (2.0)	<0.001
	Negros Occidental	176	12.7 (2.3)	12.7 (2.1)	14.4 (2.0)	12.9 (1.9)	
Sex	Female	129	13.6 (2.2)	14.0 (2.2)	14.9 (2.1)	13.4 (1.9)	0.221
	Male	317	13.4 (2.5)	13.5 (2.2)	14.5 (2.0)	13.3 (2.0)	
Age category, years	18–40	197	14.2 (2.3)	14.2 (2.1)	14.9 (1.9)	14.0 (1.9)	<0.001
	41–65	192	13.0 (2.3)	13.4 (2.0)	14.6 (2.0)	12.8 (1.8)	
	>65	57	12.3 (2.5)	12.7 (2.7)	13.9 (2.3)	12.8 (1.9)	
Marital status	Single	188	13.9 (2.5)	14.0 (2.2)	14.8 (2.0)	13.9 (2.0)	<0.001
	Married	203	13.2 (2.3)	13.6 (2.0)	14.7 (1.9)	13.0 (1.8)	
	Divorced/separated	10	12.9 (1.8)	12.7 (2.3)	13.2 (2.4)	12.6 (1.6)	
	Widowed	45	12.5 (2.3)	12.9 (2.5)	14.1 (2.1)	12.7 (1.9)	
Maximum education obtained	Primary	145	12.5 (2.2)	13.1 (2.1)	14.3 (2.1)	12.6 (1.8)	<0.001
	Secondary	168	13.4 (2.4)	13.8 (2.1)	14.8 (2.0)	13.2 (1.8)	
	Tertiary	121	14.6 (2.3)	14.3 (2.2)	14.8 (1.9)	14.5 (1.8)	
	Vocational	12	13.3 (2.0)	12.7 (2.2)	14.6 (1.3)	13.2 (2.0)	
Smoking status	No or ex-smoker	369	13.6 (2.3)	13.8 (2.0)	14.7 (1.9)	13.4 (1.9)	0.047
	Yes	77	12.8 (2.8)	13.1 (2.7)	14.1 (2.5)	12.8 (2.2)	
Alcohol consumption pre-TB	Daily	77	12.5 (2.5)	12.9 (1.9)	14.3 (2.0)	12.8 (1.8)	0.013
	Weekly or monthly	99	13.6 (2.3)	13.5 (2.1)	14.5 (2.0)	13.3 (1.9)	
	Rarely/never	270	13.7 (2.4)	13.9 (2.2)	14.8 (2.0)	13.5 (2.0)	
Household food security	Secure	234	14.1 (2.2)	14.1 (2.1)	15.0 (2.0)	14.1 (1.8)	<0.001
	Moderate insecurity	105	12.8 (2.4)	13.2 (2.3)	14.4 (2.2)	12.7 (2.0)	
	Severe insecurity	107	12.6 (2.4)	13.1 (2.0)	14.2 (1.9)	12.4 (1.7)	
Ability to work affected	No	236	13.6 (2.4)	14.0 (2.2)	14.9 (2.0)	13.3 (2.0)	<0.001
	Yes	208	13.3 (2.5)	13.3 (2.1)	14.3 (2.0)	13.3 (1.9)	

Money shortages to cover TB expenses	No	192	14.2 (2.1)	14.2 (2.1)	15.0 (1.9)	14.1 (2.0)	<0.001
	Yes	254	12.9 (2.5)	13.3 (2.2)	14.4 (2.1)	12.8 (1.7)	

TB = tuberculosis; SD = standard deviation.

Supplementary Table S3 Domain scores in 446 persons on drug-susceptible TB treatment regimens by TB-related factors

		<i>n</i>	Health-related Quality of Life domain, mean (SD)				Global <i>P</i> value*
			Physical	Psychological	Social	Environmental	
TB treatment phase	Intensive	240	13.0 (2.5)	13.4 (2.3)	14.6 (2.1)	13.2 (1.9)	0.001
	Continuation	206	14.0 (2.2)	13.9 (2.0)	14.7 (1.9)	13.5 (2.0)	
Current treatment side effects	Yes	134	12.6 (2.6)	13.1 (2.6)	14.4 (2.2)	12.9 (2.0)	<0.001
	No	312	13.8 (2.3)	13.9 (1.9)	14.8 (1.9)	13.5 (1.9)	
TB treatment category	Category I	307	13.8 (2.2)	14.0 (2.1)	14.9 (1.9)	13.5 (1.9)	<0.001
	Category II	139	12.5 (2.7)	13.0 (2.3)	14.0 (2.2)	12.9 (2.0)	
TB bacteriologically confirmed	No	299	13.5 (2.5)	13.7 (2.2)	14.7 (1.9)	13.2 (1.9)	0.581
	Yes	139	13.3 (2.3)	13.6 (2.2)	14.5 (2.2)	13.4 (2.0)	
Programmatic TB category	New case	309	13.8 (2.2)	13.9 (2.0)	14.9 (1.9)	13.5 (1.9)	<0.001
	Relapse/treatment failure/treatment after loss to follow-up/previous treatment outcome unknown	134	12.5 (2.7)	13.0 (2.4)	14.0 (2.1)	12.8 (2.0)	
Number of days adherent in last 7 days		442					0.001

TB = tuberculosis; SD = standard deviation.

Supplementary Table S4. Multivariable multivariate regression analysis of health-related quality of life (HrQoL) in persons on drug-sensitive TB treatment regimens in Manila with HIV status/test result available

		Hr-QoL domain, linear regression coefficient (95% CI)				Global P value
		Physical	Psychological	Social	Environmental	
Sex	Female					0.106
	Male	-0.87 (-1.63 to -0.10)*	-0.88 (-1.59 to -0.17)*	-0.72 (-1.47 to 0.03)	-0.64 (-1.27 to 0.00)	
Age (years)	18-40					0.012
	41-65	-0.53 (-1.20 to 0.14)	-0.68 (-1.30 to -0.05)*	-0.30 (-0.96 to 0.35)	-0.64 (-1.19 to -0.08)*	
	>65	-1.47 (-2.62 to -0.33)*	-0.93 (-1.99 to 0.13)	-0.33 (-1.45 to 0.79)	0.05 (-0.90 to 1.01)	
Maximum education obtained	Primary					<0.001
	Secondary	0.79 (0.03 to 1.54)*	0.57 (-0.13 to 1.28)	0.41 (-0.33 to 1.16)	1.03 (0.40 to 1.66)*	
	Tertiary	0.90 (0.03 to 1.77)*	0.19 (-0.61 to 1.00)	-0.41 (-1.26 to 0.44)	1.40 (0.68 to 2.13)*	
	Vocational	1.32 (-1.06 to 3.70)	0.40 (-1.81 to 2.60)	0.54 (-1.79 to 2.87)	1.23 (-0.75 to 3.21)	
Household food security	Secure					<0.001
	Moderate insecurity	-0.73 (-1.47 to 0.02)	-0.80 (-1.49 to -0.11)*	-0.76 (-1.48 to -0.03) *	-1.26 (-1.87 to -0.64) *	
	Severe insecurity	-0.91 (-1.72 to -0.10) *	-1.30 (-2.05 to -0.55) *	-2.17 (-2.96 to -1.38) *	-1.65 (-2.33 to -0.98) *	
Moderate/severe Undernutrition	No: BMI<17kg/m ²					0.212
	Yes: BMI≥17kg/m ²	-0.28 (-1.00 to 0.44)	-0.69 (-1.36 to -0.02) *	-0.00 (-0.70 to 0.70)	-0.45 (-1.05 to 0.15)	
Inflammation	No: CRP <5 g/l					0.024
	Yes: CRP 5+ g/l	-1.17 (-2.06 to -0.28) *	-1.14 (-1.96 to -0.31) *	-1.15 (-2.02 to -0.28) *	-0.79 (-1.53 to -0.05) *	
Hand grip strength		0.06 (0.03 to 0.10) *	0.02 (-0.01 to 0.05)	0.02 (-0.02 to 0.05)	0.01 (-0.02 to 0.04)	

Phase of treatment	Intensive Continuation	0.95 (0.33 to 1.58) *	0.59 (0.01 to 1.17) *	0.02 (-0.59 to 0.63)	0.08 (-0.44 to 0.59)	0.010
TB treatment category	Category 1					
	Category 2	-0.38 (-0.96 to 0.20)	-0.34 (-0.88 to 0.20)	-0.56 (-1.13 to 0.01)	0.09 (-0.40 to 0.57)	0.027
Current treatment side effects	No					
	Yes	0.33 (-0.34 to 1.01)	0.36 (-0.27 to 0.98)	0.24 (-0.42 to 0.90)	0.41 (-0.15 to 0.97)	0.709
Ability to work affected	No					
	Yes	-0.53 (-1.09 to 0.03)	-0.66 (-1.19 to -0.14) *	-0.57 (-1.12 to -0.02) *	-0.29 (-0.76 to 0.18)	0.063
Number of days adherent in last 7 days		0.06 (-0.05 to 0.16)	0.03 (-0.07 to 0.13)	0.06 (-0.05 to 0.16)	0.09 (0.00 to 0.18)	0.246
Positive HIV test result	No					
	Yes	-0.07 (-0.88 to 0.74)	-0.49 (-1.25 to 0.26)	-0.12 (-0.91 to 0.67)	0.51 (-0.16 to 1.19)	0.014

Based on N=225 after further exclusion of Negros participants and additional missing values from persons attending clinics in Manilla (Negros m=137, HIV m=30).

* Bold type indicates 95% CIs excluding the null effect.